Leukemia Research
Volume 30, Issue 4 , Pages 407-413 , April 2006

Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia

  • Wen-Lin Xu

      Affiliations

    • Department of Hematology, The Affiliated People's Hospital, Jiangsu University, 8 Dianli Road, Zhenjiang 212002, PR China
    • Corresponding Author InformationCorresponding author. Tel.: +86 511 5246930; fax: +86 511 5234387.
    • ,
  • Hui-Ling Shen

      Affiliations

    • Department of Hematology, The Affiliated People's Hospital, Jiangsu University, 8 Dianli Road, Zhenjiang 212002, PR China
    • ,
  • Zhong-Fang Ao

      Affiliations

    • Department of Hematology, The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, PR China
    • ,
  • Bao-An Chen

      Affiliations

    • Department of Hematology, The Affiliated Zhong-Da Hospital, Southeast University, Nanjing 210009, PR China
    • ,
  • Wei Xia

      Affiliations

    • Department of Hematology, The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, PR China
    • ,
  • Feng Gao

      Affiliations

    • Department of Hematology, The Affiliated Zhong-Da Hospital, Southeast University, Nanjing 210009, PR China
    • ,
  • Yong-Ning Zhang

      Affiliations

    • Department of Hematology, The Affiliated People's Hospital, Jiangsu University, 8 Dianli Road, Zhenjiang 212002, PR China

Received 26 May 2005 ,Accepted 8 August 2005.

References 

  1. Stahnke K, Boos J, Bender-Gotze C, Ritter J, Zimmermann M, Creutzig U. Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia. 1998;12:1534
  2. Steinmetz HT, Schulz A, Staib P, Scheid C, Glasmacher A, Neufang A, et al. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Ann Hematol. 1999;78:418
  3. van den Heuvel-Eibrink MM, Wiemer EAC, de Boevere MJ, van der Holt B, Vossebeld PJM, Pieters R, et al. MDR-1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood. 2001;97:3605
  4. Casale F, D’Angelo V, Addeo R, Caraglia M, Crisci S, Rondelli R, et al. P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia. Oncol Rep. 2004;12:1201
  5. Tafuri A, Gregorj C, Petrucci MT, Ricciardi MR, Mancini M, Cimino G, et al. MDR-1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood. 2002;100:974
  6. Willman CL. Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR-1). Leukemia. 1996;10:S33
  7. List AF. Multidrug resistance: clinical relevance in acute leukemia. Oncology (Huntingt). 1993;7:23
  8. Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood. 1993;81:2215
  9. Litman T, Zeuthen T, Skovsgaard T, Stein WD. Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim Biophys Acta. 1997;1361:169
  10. Liu ZL, Hirano T, Tanaka S, Onda K, Oka K. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells. J Pharm Pharmacol. 2003;55:1531
  11. Fang JH, Fang YH. Tetrandine: pharmacology and clinical usefulness. Chin Pharmaceutic. 1996;31:454
  12. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813
  13. Preisler HD, Gopal V. Regrowth resistance in leukemia and lymphoma: the need for a new system to classify treatment failure and for new approaches to treatment. Leuk Res. 1994;18:149
  14. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649
  15. Arceci RJ, Stieglitz K, Bras J, Schinkel A, Baas F, Croop J. Monoclonal antibody to an external epitope of the human MDR-1 P-glycoprotein. Cancer Res. 1993;53:310
  16. Leith CP, Chen IM, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, et al. Correlation of multidrug resistance (MDR-1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-1−/efflux+ and MDR-1+/efflux-cases. Blood. 1995;86:2329
  17. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719
  18. Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood. 1996;88:756
  19. Rizzieri DA, Ibom VK, Moore JO, DeCastro CM, Rosner GL, Adams DJ, et al. Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia. Clin Cancer Res. 2003;9:663
  20. Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB, et al. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukaemia: children's cancer group study 2951. J Clin Oncol. 2003;21:2940
  21. Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, et al. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol. 1997;15:1796
  22. Ossenkoppele GJ, Graveland WJ, Sonneveld P, Daenen SMGJ, Biesma DH, Verdonck LF, et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood. 2004;103:2908
  23. Putney JW. Pharmacology of capacitative calcium entry. Mol Interventions. 2001;1:84
  24. Cheng JT. Review: drug therapy in Chinese traditional medicine. J Clin Pharmacol. 2000;l40:445
  25. Sonneveld P, Burnett A, Vossebeld P, Ben-Am M, Rosenkranz G, Pfister C, et al. Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia. Hematol J. 2000;1:411
  26. Lee EJ, George SL, Caligiuri M, Szatrowski TP, Powell BL, Lemke S, et al. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukaemia: results of cancer and leukemia group B study 9420. J Clin Oncol. 1999;17:2831
  27. Chauncey TR, Rankin C, Anderson JE, Chen I, Kopecky KJ, Godwin JE, et al. A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617. Leuk Res. 2000;24:567
  28. Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites. Proc Natl Acad Sci USA. 1989;86:695
  29. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR-1/P-glycoprotein, MRP1, and LRP in acute myeloid leukaemia: a southwest oncology group study. Blood. 1999;94:1086
  30. den Boer ML, Pieters R, Kazemier KM, Rottier MMA, Zwaan CM, Kaspers GJL, et al. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood. 1998;91:2092
  31. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, et al. Acute myeloid leukemia in the elderly: assessment of MDR-1 and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy, a southwest oncology group study. Blood. 1997;89:3323
  32. Indolfi P, Casale F, D’Angelo V, Addeo R, Crisci S, Pota E, et al. P-glycoprotein (p-gp) expression and function as an independent prognostic factor in childhood acute lymphoblastic leukaemia. ASCO Meet Abstr. 2004;22:8503
  33. van der Kolk DM, de Vries EGE, van Putten WLJ, Verdonck LF, Ossenkoppele GJ, Verhoef GEG, et al. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res. 2000;6:3205

PII: S0145-2126(05)00313-9

doi: 10.1016/j.leukres.2005.08.005

Leukemia Research
Volume 30, Issue 4 , Pages 407-413 , April 2006

Article Tools

* Image Usage & Resolution